Study of TQB2450 Combined With Anlotinib in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1),which
prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell
activity, thus enhancing immune response and has potential to treat various types of tumors.
As a novel multitarget tyrosine kinase inhibitor for tumor angiogenesis and proliferative
signaling，anlotinib is approved for the treatment of patients with locally advanced or
metastatic non-small cell lung cancer (NSCLC) who have undergone progression or recurrence
after ≥ 2 lines of systemic chemotherapy. The Phase III study showed that the Overall
Survival (OS), Progression-Free Survival (PFS) and Overall Response Rate (ORR) were
significantly better than placebo group.